AegirBio, a leading innovator in saliva-based diagnostics solutions, today announces that it will focus towards pioneering advancements in Therapeutic Drug Monitoring (TDM) through the development of a groundbreaking platform under the RadX initiative, coupled with a robust business development strategy.

In line with this decision, AegirBio will continue to offer its current MagniaReader and the two TDM tests for the MagniaReader, albeit exclusively for research purposes and will thus not uphold the CE markings for the said PoC tests for infliximab (Remicade) and natalizumab (Tysabri). These resources will be dedicated to bolstering the core focus areas of the company.

Marco Witteveen, CEO of AegirBio, expressed enthusiasm about this strategic pivot, stating, "This decision enables us to channel our energies towards delivering a sophisticated platform that aligns with the evolving needs and expectations of both physicians and patients. It empowers us to forge a path towards cutting-edge healthcare solutions."

AegirBio is poised to leverage this shift in strategy to spearhead the development of a state-of-the-art platform, positioning itself at the forefront of the healthcare industry. This pivotal move underscores the company's commitment to advancing healthcare accessibility and patient-centric solutions.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

This information is such information that Aegirbio AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person.

Related link:
Cision